Laws · federal-enforcement

Challenges to DEA Medical Marijuana Enforcement Ramp Up

Law360 reports a growing wave of legal challenges to DEA enforcement against medical marijuana, adding pressure on a federal posture already in flux.

By Niko Adamou, Hemp & THCA ReporterPublished November 21, 20264 min read
A gavel resting on dollar bills atop the American flag, symbolizing justice and finance.

A gavel resting on dollar bills atop the American flag, symbolizing justice and finance.

Legal challenges to DEA enforcement of federal marijuana law against medical programs are escalating, according to a Law360 report published Nov. 21, 2026. For operators and hemp-derived THC sellers, the outcome could redefine federal enforcement risk. Few details are public so far.

Challenges are multiplying, and the signal is thin on specifics

Law360 reported Nov. 21, 2026, that challenges to DEA medical marijuana enforcement are ramping up, but the public summary doesn't name the cases, courts, or plaintiffs.

That limits what can be said with precision. The Law360 item, as indexed by Google News, carries a headline and a publication tag. The full text sits behind the outlet's paywall, and CannIntel hasn't independently verified the underlying filings.

Treat this as a directional marker, not a docket summary. Still, the direction is clear enough: more litigants are testing whether the DEA can keep enforcing the Controlled Substances Act against state-licensed medical activity.

Why the enforcement question keeps coming back

Marijuana remains a Schedule I controlled substance under federal law, which is the legal hook for every DEA enforcement action against medical operators.

State medical programs operate in a gap. Congress has repeatedly used appropriations language to restrict the Justice Department from spending funds to interfere with state medical marijuana programs. Courts have read that rider in varying ways, and it has to be renewed in spending legislation, so it's a temporary shield, not a statutory one.

Challenges tend to cluster around a few theories:

  • Appropriations riders: whether federal spending limits bar prosecution of state-compliant actors.
  • Scheduling: whether Schedule I placement still holds up against the medical record.
  • Administrative process: whether DEA actions followed required rulemaking and notice procedures.

Which of these theories drive the current wave isn't specified in the signal. That's the gap to watch as filings surface.

What it means for hemp, THCA, and the total-THC fight

Any ruling that narrows DEA's reach over medical marijuana could ripple into hemp-derived THC products, where the delta-9-versus-total-THC dispute is still unsettled.

The chemistry is what makes the overlap real. Raw hemp flower can carry high levels of THCA, which converts to delta-9 THC through decarboxylation when heated. Under the 2018 Farm Bill, hemp is defined by a delta-9 THC concentration of no more than 0.3% on a dry-weight basis. Whether that limit is measured on delta-9 alone or on total THC, counting post-decarboxylation potential, is the crux of the loophole fight.

Regulators and courts haven't settled it uniformly. Enforcement posture on THCA flower, and on products made through isomerization of CBD into delta-8 or other cannabinoids, varies by state and by agency. A federal court narrowing DEA authority in the medical context wouldn't directly resolve that, but it would signal how far judges are willing to police the boundary of agency power, and hemp litigants will cite it.

Don't overread the link. Medical marijuana and hemp sit under different statutory definitions. They share an enforcement agency and a lot of the same defendants' lawyers.

What operators should do now

Operators should treat the current enforcement environment as unsettled and avoid assuming either a federal green light or a crackdown.

Practical steps while the filings come into view:

  1. Pull the Law360 report and identify the specific courts and cases once names are public.
  2. Confirm whether your state license and activities fall inside any appropriations-rider protection.
  3. For hemp sellers, document total-THC testing and decarboxylation potential on every lot, regardless of which standard your state applies.
  4. Brief counsel on how an adverse or favorable ruling would change your exposure.

None of that is a prediction. It's risk hygiene. A ramp-up in challenges means more rulings are coming, and some will cut against operators.

For full background on the enforcement fight, see the CannIntel topic hub on DEA medical marijuana enforcement. Three pressure points are worth tracking: the Drug Enforcement Administration, the Department of Justice, and Congress's spending bills, along with state regulators in California and elsewhere.

It's unsettled. Expect enforcement to vary by district, by agency, and by product category until courts say otherwise.

Frequently asked questions

What did Law360 report about DEA medical marijuana enforcement?

Law360 reported on Nov. 21, 2026, that challenges to DEA medical marijuana enforcement are ramping up. The publicly available summary doesn't identify specific cases, courts, or plaintiffs, and the full article is paywalled.

Why can the DEA still enforce against state medical marijuana programs?

Marijuana remains a Schedule I substance under the federal Controlled Substances Act. Appropriations riders have limited Justice Department spending against state medical programs, but they require renewal and courts have interpreted them differently.

How does this affect hemp and THCA products?

Indirectly. Hemp falls under the 2018 Farm Bill's 0.3% delta-9 THC limit, while medical marijuana sits under the Controlled Substances Act. A ruling limiting DEA authority could still influence how courts view agency power over hemp-derived THC.

What is the delta-9 versus total-THC dispute?

It concerns whether the 0.3% hemp limit counts only delta-9 THC or also THCA that converts to delta-9 through decarboxylation. Regulators and courts haven't applied one standard uniformly, so enforcement varies.

Sources

DEA enforcementmedical marijuanaSchedule Iappropriations riderTHCAhemp loophole
The CannIntel Daily

The cannabis newsletter you forward to your team.

Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.

No spam. Unsubscribe with one click. 21+ only.

Related from Laws

More from the newsroom